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Abstract
Background—The Patient Reported Outcomes Measurement Information System (PROMIS®) 
has developed pediatric self-report scales measuring several unidimensional health attributes 
(domains) suitable for use in clinical research, but these measures have not yet been validated in 
sickle cell disease (SCD).
Procedure—A convenience sample of SCD children, aged 8-17 years, from two Sickle Cell 
programs was recruited at routine clinic visits, including some for hydroxyurea monitoring or 
monthly transfusions. Children completed PROMIS pediatric items using an online data collection 
platform, the PROMIS Assessment Center website.
Results—A total of 235 participants (mean age 12.5 ± 2.8 years, 49.8% female) participated in 
the study. Adolescents (ages 12-17 years) reported significantly higher pain interference and 
depressive symptoms, and worse lower extremity physical functioning domain scores compared to 
younger children (ages 8-11 years). Female participants reported significantly higher pain 
interference, fatigue, and depressive symptoms, and worse lower extremity physical functioning 
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domain scores compared with their male counterparts. Participants with hip or joint problems that 
limited usual activities reported significantly higher pain, fatigue, and depressive symptoms 
scores, and worse upper/lower extremity physical functioning scores as did participants who had 
experienced sickle pain in the previous seven days.
Conclusions—PROMIS pediatric measures are feasible in a research setting and identify 
expected differences in known group comparisons in a sample of SCD children. The large domain 
score differences between those with or without SCD-related complications suggest the potential 
usefulness of these measures in clinical research, but further validation studies are needed, 
particularly in clinical practice settings.
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Introduction
Patient or parent reports of symptom intensity or frequency, particularly of pain, are used 
routinely in the clinical management of children with sickle cell disease (SCD) [1], and are 
being increasingly used as outcome measures in clinical trials of new therapies for vaso-
occlusion [2]. Additional assessment of other aspects of health-related quality of life 
(HRQOL) such as physical function, psychological/emotional function, and social function 
may provide a more complete picture of the impact of the many possible SCD complications 
on an individual and their family [3].
A number of studies have examined the HRQOL in children and adolescents with SCD [4]. 
Most of these studies used the Peds QL ver 4.0™ [5], often with its additional 
Multidimensional Fatigue Scales [6], given its availability and prior use in healthy childhood 
populations [7,8] and a large variety of chronic diseases and conditions [9]. The largest of 
these SCD studies enrolled 1,772 participants (53% males) in their baseline state of health 
with a mean age of 9.6 years (SD 4.7) and a typical distribution of sickle hemoglobinopathy 
types [10]. Multiple regression models controlling for hemoglobinopathy type, sex, and age 
suggested that parent reports of physical functioning and sleep/rest fatigue worsened in 
response to pain or avascular necrosis of hips/shoulders (AVN), while school functioning 
worsened in response to pain or asthma. Prior occurrence of sickle pain, and to a lesser 
extent asthma, negatively influenced child reports on almost all functioning and fatigue 
scales. Peds QL scale scores are sensitive to changes in acute SCD complications such as 
pain [11] and to social/demographic variables such as family income [12]. A modified 
version of the Peds QL is now available with additional SCD specific questions [13].
To provide the next generation of standardized patient-reported outcome (PROs) measures in 
pediatric and adult health with improved reliability and validity, the National Institutes of 
Health (NIH) funded the Patient Reported Outcomes Measurement Information System 
(PROMIS®; www.nihpromis.org) as part of the NIH Roadmap for Medical Research 
Initiative [14]. The PROMIS Pediatric multisite initiative, similar to the adult PROMIS 
project, created pediatric self-report scales measuring the unidimensional health attributes 
(domains) of depressive symptoms, anxiety, anger, pain interference, peer relationships, 
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fatigue, physical functioning - mobility, physical functioning - upper extremity, and asthma 
impact [15]. The items for these domains were initially developed through an extensive 
review of the literature, expert review, and qualitative methods (focus groups and cognitive 
interviewing) [16-18]. Subsequent quantitative analyses utilized item response theory (IRT) 
methods to develop item banks on a common metric suitable for computerized adaptive 
testing (CAT), in addition to creating unidimensional static (fixed-length) short forms 
suitable for multiple modes of administration [15]. These measures are publically available 
at no cost, offer flexible modes of administration, provide parent-proxy report scales for 
those unable to provide self-report [19] including children 5-7 years old [20], can be 
customized to the unique features of the disorder [21], and potentially can provide the ability 
to link measures across pediatric and adult age groups [22], a unique advantage for lifespan 
researchers.
As part of a larger validation study of the PROMIS pediatric measures in a variety of 
illnesses experienced by children and adolescents including cancer, kidney disease, asthma, 
obesity, arthritis, or disability requiring long-term rehabilitation care [23], we evaluated the 
PROMIS pediatric measures in a sample of SCD children and adolescents, aged 8- to 17-
years old, with a range of SCD-related symptoms during routine non-acute care healthcare 
encounters.
Methods
This study was approved by the Institutional Review Boards (IRB) for Emory University, 
University of North Carolina, Chapel Hill, Duke University, and the Children's Healthcare of 
Atlanta prior to participant enrollment.
Recruitment
A convenience sample of SCD patients aged 8-17 years followed at 2 large Sickle Cell 
programs (Children's Healthcare of Atlanta and Duke University) was recruited over an 8 
month period at the time of routine clinic visits. To facilitate the known group comparisons, 
individuals were recruited who were likely to be relatively asymptomatic including patients 
presenting for monthly transfusions or who were not sufficiently symptomatic for 
hydroxyurea. Similarly, individuals presenting to clinic for monthly hydroxyurea monitoring 
were recruited as they were expected to have a range of symptomatology reflecting their 
degree of response to hydroxyurea treatment.
Eligible children and their parent/guardian had to be able to read and speak English, possess 
functional computer skills (defined as able to see and interact with a computer screen, 
keyboard, and mouse), and be willing to give written assent/permission for study 
participation. Exclusion criteria were children and adolescents who had any concurrent 
medical or psychiatric condition which precluded study participation, cognitive or other 
impairment (e.g., visual) that interfered with completing a self-administered computer-based 
questionnaire.
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Enrollment and data collection
After consent/assent was obtained by study staff, parents completed the demographic and 
SCD-related medical history items on the computer and then children completed the 
PROMIS pediatric measures. Participants completed the PROMIS measures using a laptop 
in a private clinic exam room or a nearby conference/consultation room. Parents were 
invited to remain with their child if they preferred; however, if they remained they were 
asked not to assist their child with responding to the items and instead allow the study team 
member who remained in the room to assist if needed. Each child or adolescent received a 
$10.00 gift certificate to help compensate for their time.
Each assenting child and adolescent was assigned a unique identification number using a 
computer-based system. No other identifiers were collected using the computerized 
assessment method. Only de-identified data were used in the analysis. The online data 
collection platform, the PROMIS Assessment Center secure website, was supported by the 
PROMIS Technology Center at the Department of Medical Social Sciences at Feinberg 
Northwestern School of Medicine, Chicago, IL.
Measures
In order to reduce respondent burden, we created a sampling plan such that each participant 
was administered between 97 and 107 PROMIS items from both the full bank (all PROMIS 
items that measure a single HRQOL domain) and short form measures (a small set of 
representative PROMIS items from each bank). Three questionnaire forms were used in this 
study: the first form (98 PROMIS items) had full item banks included for mobility, pain 
interference, and fatigue and short forms for upper extremity functioning and depression; the 
second form (107 PROMIS items) had the full item banks for pain interference, fatigue, 
anxiety, and peer relationships and short forms for upper extremity functioning and 
depression; the third form (97 PROMIS items) had the full item banks for upper extremity 
functioning and depression and short forms for mobility, pain interference, fatigue, anxiety, 
peer relationships, and anger. As only one form had the anger item short form, a lower 
number of participants completed the anger measure (see Supplemental Table I for the 
sampling matrix of the measures). The three questionnaire forms were randomly assigned by 
the computer for each participant and the actual sequence of the measures was also 
randomly determined. The study team member working with the participant did not know 
which form was being administered.
Parents completed a 16-item demographic form online and a 15-item form detailing their 
child's SCD treatment, occurrence of chronic complications in the previous 6 months, and 
frequency of acute complications. An affirmative response by the parent to the question, 
“Was your child treated for pain at home in the last 7 days?” was used to indicate the 
presence of pain experienced by their child during the previous 7 days. No distinction was 
made between pharmacologic or non-pharmacologic treatments. Sickle hemoglobinopathy 
type, the occurrence of chronic transfusion in the previous 12 months, and the usage of 
hydroxyurea during the previous 6 months (but not adherence) were verified from medical 
records.
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Eight PROMIS pediatric measures (Physical Functioning-Mobility, Physical Functioning-
Upper Extremity, Pain Interference, Fatigue, Depressive Symptoms, Anxiety, Peer 
Relationships, and Anger) were assessed. These measures elicit responses based on the 
previous 7 days using a 5-point response option ranging from “never” to “almost always” in 
most measures and from “with no trouble” to “not able to do” for physical functioning 
measures. Higher scores indicate more of the measured HRQOL domain being assessed, 
which signifies worse severity for depression, anxiety, anger, fatigue, and pain interference 
and better functioning for physical functioning-mobility, physical functioning-upper 
extremity, and peer relationships. Each participant's completed PROMIS pediatric measure 
was scored on a T-score metric with a mean of 50 and a standard deviation of 10 based on 
the original reference sample of a diverse group of children and adolescents [24].
These and other PROMIS pediatric measures are available at no cost for download at 
www.nihpromis.org or www.healthmeasures.net after a simple registration process. These 
websites also provide the characteristics of the measures, which are also available in 
associated publications [25-30]. Guidance for their use and scoring as fixed short forms or as 
computer adapted tests are available at these websites, as well as www.assessmentcenter.net, 
which provides a software platform for administration and scoring as used in our study.
Statistical Analysis
Average IRT scores for each of the eight measures were calculated both overall and by 
different demographic and clinical characteristics. Mean differences were compared using t-
tests. Unadjusted linear regression was used to examine the relationship between each 
measure and, in the previous 6 months, the number of parent reported: 1) home-managed 
pain episodes, 2) emergency department-managed pain episodes, and 3) hospitalizations.
Simultaneous adjusted regression with full information maximum likelihood (FIML) 
estimation was used to determine whether age, sex, genotype, hip pain, or pain in the past 
week were associated with any PROMIS measures. Simultaneous regression – which had all 
eight PROMIS pediatric measures being regressed at the same time upon the five 
characteristics – was used, because each PROMIS measure was correlated to some degree 
with each other in bivariate analyses. FIML estimation was used so that all available data for 
each PROMIS measure were included. FIML estimation also assumed that missing data was 
related to some of the observed data (MAR) as opposed to missing completely at random 
(MCAR), which is a more likely scenario for this dataset as the sampling plan had 
participants complete forms for only certain PROMIS measures. Analyses were conducted 
using SAS version 9.3 (SAS Institute, Cary, North Carolina).
Results
Study Participants
A total of 235 participants (mean age 12.5 ± 2.8 years, 49.8% female) participated in the 
study (Emory 169, Duke 66). Most participants had an SS genotype (76.5%), while 16.7% 
had SC, 4.7% had Sickle B+thalassemia, and 1.0% had Sickle B0thalassemia (Table I). 
Almost all participants were self-identified by parents/guardians as African American and 
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not of Hispanic ethnicity. At the time of the study 19% were receiving chronic transfusions, 
almost all for primary stroke prevention while 43.0% had been prescribed hydroxyurea (66% 
of those participants with SS or SB0thalassemia not on chronic transfusion) for at least 6 
months. Age or sex was not statistically significantly different (p>0.05) between the 
individuals receiving chronic transfusion, hydroxyurea, or supportive care (Table I).
Additional medical comorbidities were not uncommon, with 26% reporting a physician 
diagnosis of asthma and 9% reporting chronic pain (Table I). Similarly, a parent report of 
recent hip or other joint problem that interfered with usual activities was reported for 17% of 
participants. In the prior 6 months, participants were reported to have had 4.9 ± 9.1 (mean ± 
standard deviation) home-managed painful episodes; 1.2 ± 2.9 ED managed painful 
episodes; and 0.7 ± 1.7 hospitalizations for pain. Thirty-one percent of participants reported 
some type of pain treatment was used at home in the previous 7 days (Table I). As expected, 
the individuals receiving chronic transfusions reported the fewest number of vaso-occlusive 
complications (Table I).
PROMIS Domain Scores
Domain scores for the sample and the number of participants completing each item bank are 
shown in Table II. Overall PROMIS pediatric scores for the children with SCD largely 
mirror values seen in the normative sample consisting of both healthy children and those 
with chronic illnesses attending general pediatric clinics with PROMIS mean scores of 50. 
The exception is that this sample of SCD children had depression and anxiety domain scores 
one-half standard deviation (5 points) better than the normative sample.
Known Group Comparisons
Adolescents (ages 12-17 years) reported significantly higher pain interference and 
depression scores, and worse lower extremity physical functioning (mobility) scores 
compared to younger children (ages 8-11 years) with SCD (Table III). Female participants 
reported significantly higher pain interference, fatigue, and depressive symptoms scores, and 
worse lower extremity physical functioning (mobility) scores compared with their male 
counterparts (Table III). There were no significant differences in any domain scores between 
participants with different genotypes (all p-values >0.05), likely reflecting that many 
participants with the more severe SS or SB0thalasemia were receiving disease-modifying 
therapies. Significantly higher pain, fatigue, and depressive symptoms scores, and worse 
lower extremity (mobility) and upper extremity (dexterity) physical functioning scores were 
reported by participants with hip or joint problems that limited usual activities (Table III, all 
p<.05), and participants who received parent-reported pain treatment at home in the past 
seven days (Table III, all p<.01). There were no significant differences in any domain scores 
between children with and without asthma (all p-values >0.05).
Simultaneous linear regression modeling (Table IV) suggested that recent vaso-occlusive 
pain, rather than age, sex, or sickle genotype, was the dominant factor explaining differences 
in reported mood symptoms (anxiety, depression) and lower extremity functioning 
(mobility). Similarly, pain, either from recent acute vaso-occlusive pain or from persistent 
bone/joint disease equally impacted pain interference and fatigue scores, consistent with the 
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impact of clinical severity observed in other pediatric chronic diseases [23]. The paradoxical 
impact of SC and SB+thalassemia hemoglobinopathy types on pain interference scores 
likely reflects the ameliorating effect of concurrent hydroxyurea or blood transfusion in most 
of the participants with SS or SB0thalassemia.
The number of pain episodes managed at home, number of emergency department visits for 
pain, and number of hospitalizations in the past 6 months were all significantly and 
positively associated with an increase in pain interference and fatigue as well as worse 
mobility scores (Table V), consistent with the impact of recent hospitalizations observed in 
other pediatric chronic diseases [23]. The frequency of hospitalizations was also associated 
with lower peer relationships domain scores.
Discussion
PRO measures help to give a voice to children and adolescents so that they can communicate 
the personal impact of disease manifestations or consequences from its treatment. Our 
findings establish the preliminary validity of PROMIS pediatric measures in children and 
adolescents with SCD, and illustrate important patient-level consequences of SCD 
complications as perceived by these patients. Similar PROMIS scores across 
hemoglobinopathy types were not unexpected given the wide range of symptomatology seen 
in pediatric SCD, and the amelioration of pain frequency provided by the hydroxyurea or 
transfusions that most of the SS and SB0thalassemia participants were receiving [31]. While 
relying only on self-report, our findings in individuals with recent or frequent acute pain, 
and in those with chronic bone complications of SCD provide important preliminary support 
for known-groups discriminant validity of the PROMIS pediatric measures, similar to 
previous findings with the Peds QL [10]. Our results also highlight the impact of 
symptomatology other than pain in children and adolescents with SCD, such as fatigue, 
physical functioning, and mood, consistent with other recent studies of fatigue in children 
[6] and adults [32] with SCD, and health-related quality of life studies using disease-specific 
measures [13,33]. Our findings suggest that the PROMIS pediatric measures are potentially 
sensitive to age and sex differences in outcomes reported in other SCD studies [32,34,35], 
such as differences generally indicating females report or experience outcomes such as pain 
interference, fatigue, and depression more frequently or intensely than do males.
There are a number of limitations to our study. Consistent with our known group analysis 
strategy, participants in our study were recruited to represent a convenience sample that was 
intentionally diverse in age, sex, hemoglobinopathies, treatments and symptomatology. Thus 
our sample was not a probability sample and findings cannot be generalized to the broader 
SCD population. This selection strategy and the cross-sectional nature of the study design 
likely reduced our ability to detect any differences related to sickle genotypes or the impact 
of transfusion or hydroxyurea treatment. Since only about 35% of the sample responded to 
the anger measure, we may have been underpowered to identify modest relationships 
between anger domain scores and clinical variables. The modest sample size also precluded 
studies of the influence of less frequent SCD complications or co-morbidities, or the impact 
of subtle cognitive impairments on the PROMIS pediatric measures scores. Similarly, a 
number of potential confounders such as race/ethnicity and socioeconomic status were not 
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examined. Several comparisons relied on results from parental reports that have their own 
limitations [36,37].
At the time this study was started, only the English versions of the PROMIS pediatric 
measures had been developed and as a result, only English-speaking participants were 
enrolled. While versions of the Pediatric PROMIS measures are now available for Spanish-
speaking individuals, these are translated versions and have not been extensively validated in 
Hispanic populations, including those with SCD.
Lastly, measure validation is an extensive process, and our results provide initial evidence 
for only the known-groups validity of PROMIS pediatric measures in children with SCD. 
Assessment of the responsiveness of the PROMIS pediatric measures to disease-related or 
treatment-related changes over time is another important attribute of the validity of the 
measures and will need to be studied. Similarly, additional longitudinal studies will need to 
examine the relationship of PROMIS pediatric measures with SCD clinical outcomes to 
establish score levels consistent with changes in meaningful clinical severity, or that suggest 
the need for clinical intervention.
In conclusion, PROMIS pediatric measures are feasible in a research setting and are valid 
indicators of PROs among children aged 8–17 years with SCD. The large differences 
between those with or without reported SCD-related complications for many of these 
measures suggests their potential usefulness in clinical trials and in clinical practice, but 
further studies are needed.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Table I
Characteristics of SCD Sample Cohort by Treatment Strategy
N (%)
Characteristic






 8 – 9 17 (16.8) 4 (8.9) 22 (24.7) 43 (18.3)
 10 – 11 22 (21.8) 13 (28.9) 16 (18.0) 51 (21.7)
 12 – 13 21 (20.8) 12 (26.7) 20 (22.5) 53 (22.6)
 14 – 15 16 (15.8) 10 (22.2) 16 (18.0) 42 (17.9)
 16 – 17 25 (24.8) 6 (13.3) 15 (16.9) 46 (19.6)
Mean age (SD) 12.7 (3.0) 12.6 (2.4) 12.1 (2.8) 12.5 (2.8)
Median age (Range) 13 (8 – 17) 13 (9 – 17) 12 (8 – 17) 12 (8 – 17)
Gender
 Male 55 (54.5) 20 (44.4) 43 (48.3) 118 (50.2)
 Female 46 (45.5) 25 (55.6) 46 (51.7) 117 (49.8)
Genotype
 SS or SB0 thalassemia 93 (92.1) 42 (93.3) 47 (52.8) 182 (77.5)
 SC or SB+ thalassemia 6 (5.9) 3 (6.7) 41 (46.1) 50 (21.3)
 Other 1 (1.0) 0 (--) 1 (1.1) 2 (0.9)
 Unknown 1 (1.0) 0 (--) 0 (--) 1 (0.4)
Parent report of hip or joint problems 
at time of visit*
 No 79 (78.2) 39 (88.6) 76 (85.4) 194 (82.9)
 Yes 22 (21.8) 5 (11.4) 13 (14.6) 40 (17.1)
Number of home-managed pain 
episodes in past 6 months**
 0 20 (20.0) 20 (44.4) 27 (30.3) 67 (28.6)
 1 – 2 33 (33.0) 7 (15.6) 31 (34.8) 71 (30.3)
 3 – 6 22 (22.0) 11 (24.4) 17 (19.1) 50 (21.4)
 ≥ 7 25 (25.0) 7 (15.6) 14 (15.7) 46 (19.7)
Mean home-managed pain episodes 
(SD)
5.7 (8.3) 3.1 (4.2) 5.0 (11.4) 4.9 (9.1)
Median home-managed pain episodes 
(Range)
2 (0 – 45) 1 (0 – 20) 2 (0 – 90) 2 (0 – 90)
Number of Emergency Department 
(ED) managed pain episodes in past 6 
monthsˆ
 0 53 (53.0) 33 (76.7) 47 (52.8) 133 (57.3)
 1 – 2 28 (28.0) 9 (20.9) 34 (38.2) 71 (30.6)
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N (%)
Characteristic





 ≥ 3 19 (19.0) 1 (2.3) 8 (9.0) 28 (12.1)
Mean ED-managed pain episodes (SD) 1.8 (4.1) 0.4 (0.8) 0.9 (1.4) 1.2 (2.9)
Median ED-managed pain episodes 
(Range)
0 (0 – 25) 0 (0 – 4) 0 (0 – 10) 0 (0 – 25)
Number of hospitalizations for pain in 
past 6 monthsˆˆ
 0 59 (59.6) 29 (65.9) 62 (69.7) 150 (64.7)
 1 – 2 26 (26.3) 13 (29.5) 26 (29.2) 65 (28.0)
 ≥ 3 14 (14.1) 2 (4.5) 1 (1.1) 17 (7.3)
Mean # hospitalizations (SD) 1.1 (2.4) 0.5 (1.0) 0.4 (0.7) 0.7 (1.7)
Median # hospitalizations (Range) 0 (0 – 20) 0 (0 – 5) 0 (0 – 3) 0 (0 – 20)
Any treatment for pain at home in past 
7 days~
 No 63 (63.0) 35 (77.8) 64 (71.9) 162 (69.2)
 Yes 37 (37.0) 10 (22.2) 25 (28.1) 72 (30.8)
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Table II
Domain Scores for SCD Cohort
Domain Number of Subjects Mean (SD)
Pain Interference 232 48.7 (13.6)
Fatigue 234 46.7 (13.0)
Depression 234 45.0 (10.3)
Anxiety 161 45.0 (11.5)
Anger 82 46.1 (12.5)
Lower Extremity Physical Functioning (Mobility) 155 50.6 (8.3)
Upper Extremity Physical Functioning (Dexterity) 234 50.6 (7.5)
Peer Relationships 161 48.5 (10.9)
SD=Standard Deviation
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